Objective: To evaluate the failure rate of cochlear implant systems across a range of European implant centers.
Cochlear implants are implantable biomedical prostheses which partially restore the sense of hearing in profoundly deaf subjects. They consist of two main components: 1) the external components consisting of a microphone, speech processor, transmitter coil and batteries and 2) the implanted component comprising the receiver electronics, the magnet (to maintain the receiver and transmitter electronics in apposition) and an electrode array that carries the electrical impulses to the auditory nerve in the cochlea. Cochlear implants have been shown to be safe and effective both in the pediatric (Beadle, McKinley, Nikolopoulos, et al., 2005) and adult populations (Francis, Chee, Yeagle, et al., 2002) and there are over one hundred thousand recipients of such implants worldwide. Unlike hearing aids, cochlear implants require a surgical intervention and are considerably more costly. Successful users become highly dependent on their systems for their daily communication, with most users wearing their systems throughout the entire day. Such dependence on this technology mandates that these systems are reliable and that data on reliability is transparent to all concerned with the implant process. Thus, when patients (or parents) select a device, comparative reliability data should be available to them to inform their choice of device. The financial cost of failure is considerable incurring the purchase of another implant system (if the warranty has been exceeded), hospitalization costs and the human resource implications of diagnosing the faulty device, counseling and reprogramming the patient. More importantly, the impact of device failure on individual patients and their families can pose a substantial burden, with disruption of school or work routines, several clinic visits and the frustration of enduring sudden or declining performance from their implant system Twomey & Archbold, 1997) . Reliability of cochlear implant systems is thus a central consideration for clinicians, patients and commissioners of healthcare alike (Balkany, Hodges, Buchman, et al., 2005) .
In order to address this issue, a group of European implant professionals convened a meeting to define standards of reporting for cochlear implantation (European Consensus Statement on Cochlear Implant Failures and Explantations, 2005) . In addition, the group commissioned a study of their own practices to determine the reliability of devices across a range of European centers. The initiative was stimulated by the concerns of clinicians who were unable to obtain unbiased reliability data on the implant systems currently in use in their clinics and thus felt unable to advise their patients in this regard. The implant centers were drawn from the major providers of implant services across Europe irrespective of their device preference.
MATERIALS AND METHODS
A questionnaire was designed (Appendix) to evaluate the incidence of device failure and was sent to (Table 1) around Europe. Each implant center was asked to make available its complete data on total device failure. Although partial or intermittent failures are of the utmost importance, they were excluded from this study as data on such failure modes is not readily available and there was likely to be an absence of agreement across centers on what exactly constituted such failures. Centers were asked to provide their total data since the inception of their programs. Only devices from companies still in operation were included-devices from the early years which are no longer commercially available were excluded.
RESULTS
Of the 34 centers contacted, 27 (79%) responded (Table 2) . Most centers began their implantation in the late 1980's with some centers having a longer experience (mean 1989, range from 1980 -1997) The Wuerzburg center felt unable to provide data for the study because of perceived concerns about litigation and confidentiality. Because MXM products were under-represented in the original clinics, 4 centers where MXM devices are used were added to in the data set to have an overview on all systems commercially available at the moment. Thus a total of 12,856 devices were available for evaluation. Of these, 488 (3.79%) were reported to have undergone a total failure as defined by the individual clinics. Table 2 provides a summary of the overall device reliability for the group broken down according to the four manufacturing concerns.
With regard to the information provided to clinics, 24 (88.9%) obtained reports from the companies when a device failure occurred. Twenty-five (92.6%)
of clinicians felt such reports should include the serial number and date of manufacture, all clinics felt information about the tests undertaken should be provided and 26 (96.3%) felt the failure mode should be described, and 24 (88.9%) wanted to know what corrective action, if any, would be instituted by the company to reduce similar failure in the future. In the matter of reporting failures to competent authorities, practice varied with 18 (66.7%) always reporting them, 3 (11.1%) occasionally doing so and as many as 6 (22.2%) never doing so. All favored the implementation of a European database to monitor device failure.
DISCUSSION
A measure of the frequency of device failures was first introduced by the pacemaker industry and was published as an ISO standard (ISO 5841-2, 2000) . The definition of "cumulative survival rate (CSR)" combines the two influencing parameters of the life of a medical device: the survival time and the percentage of surviving devices. Therefore, cumulative survival shows the percentage of devices surviving at a given time. Survival rates of 98% and higher are common values in the pacemaker industry (Guidant, 2005) Cochlear Ltd., the manufacturer of the Nucleus device, was the first cochlear implant company which introduced this measure into the field of cochlear implants (von Wallenberg, Brinch, Money, et al., 1993) . Today, all implant companies claim their reliability in CSR. Although the calculation of the CSR has been standardized, the definition of the failure modes included in the calculation has not. Thus, excluding special modes of device failures (e.g. impact failures) results in a device appearing to have a much more favorable CSR than it actually merits (Maurer, Marangos, & Ziegler, 2005) . Without knowledge of the criteria on which the CSRs are based they cannot be used as a basis to compare reliability across the products of different companies. This should become better in the future as the "European Consensus Statement on Cochlear Implant Failures and Explantations" addresses this problem and clarifies which data manufacturers have to include into their CSR calculations. In the meantime, a modified measure called "cumulative failure rate" (which is derived by simply subtracting the CSR from 100%) has been proposed as an alternative to CSR. Although the graphic representation for the cumulative failure rate might be easier to understand, CSR should continue to be used because it is based on an international standard. The data of the present study do not reflect the CSRs of different devices as this was not the intention of the questionnaire. It was tations, 2005) . The information in this article will hopefully act as a catalyst towards establishing and maintaining a comparative European data base which is independent of the industry but which maintains collaborative links with it. This will allow greater transparency on failures and facilitate comparison between devices, different populations and failure modes (Tambyraja, Gutman, & Megerian, 2005) . In particular, it should differentiate between adult and pediatric users due to their differing incidence of impact failure (Kempf, Tempel, Johann, et al., 1999) . Such information will enable parents to make more informed decisions about the choice of implant system for their child and will promote better corporate governance within the industry. In the unlikely event of later device failure, parents can be reassured that their initial decision was well founded, and based on what was an accurate report of the reliability of the device they chose for their child. An accurate database will also help health care commissioners, both in terms of dictating their purchasing strategy and by ensuring that good monitoring systems are in place to inform them about subsequent device failure (Raz, 2005) . Transparency on device failure will also help manufacturers identify design features that may make their products more prone to failure and thus help them address such features to improve the quality of their product (Lehnhardt, von Wallenberg, & Brinch, 2000) . The adoption of the European Consensus on cochlear implant failures is a first step towards providing the kind of information that users, clinicians and healthcare commissioners need to inform their decisionmaking in this rapidly advancing field. 
